SING GEORGE L sold $1.9M of REGN

SING GEORGE L sold 2,000 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $958.97 ($956.96–$960.26, $1.92M total) across 4 trades over 2026-11-16 to 2026-11-17.

Original reporting
SEC EDGAR · SING GEORGE L
Published Nov 18, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Bearish
medium confidence
Mentioned
$REGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNBearishLow
01

Why it matters

The key new information is the director’s open-market sale details (shares, dates, price range, and total value). This can influence short-term sentiment but does not provide new operational or financial guidance.

02

Market read

Traders may briefly reassess sentiment around REGN due to director selling, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamental news.

03

What to watch

The filing does not state motivation, and the sale size, while notable, is not large enough here to imply a change in corporate strategy or near-term fundamentals.

Relevance 6/10Novelty 5/10Timing: filed 2026-11-18, covering sales dated 2026-11-16 to 2026-11-17

Background

The article is an SEC Form 4 insider transaction disclosure for Regeneron Pharmaceuticals, filed via SEC EDGAR.

Company-level read

Ticker impact

$REGNBearishMedium confidence
Context

SEC Form 4 shows director Sing George L sold 2,000 REGN shares in open-market trades totaling about $1.92M, under no 10b5-1 plan.

Expected impact

Likely limited near-term pressure as traders weigh the sale against ongoing fundamentals, with most impact confined to sentiment.

Evidence & confidence

The article is a primary insider transaction filing with defined size and timing, but it does not include earnings, guidance, legal/regulatory developments, or operational catalysts.

Market effects

Minimal, as this is company-specific insider activity without sector-wide signal.

None expected beyond typical single-name sentiment effects.

None expected.

Counterpoint

Director sales are often routine liquidity events; without a 10b5-1 plan, the sale could still be unrelated to company outlook.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    US-listed biotech subject of the Form 4 insider sale disclosure.

  • Sing George L

    Director who sold 2,000 shares across four open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.